News
BMS and Dragonfly Therapeutics Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program
Bristol Myers Squibb and Dragonfly Therapeutics, Inc. announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted...
Drug Research
Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration
Gilead Sciences, Inc. and Tango Therapeutics announced an expanded strategic collaboration focused on the discovery, development and commercialization of innovative targeted immune evasion therapies...
Clinical Trials
Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased...
Clinical Trials
DSG and Bestat Partner in Building COVID-19 Clinical Trials in Singapore
DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry along with their CRO partner, Bestat Pharmaservices Corp....
Press Releases
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launched to accelerate the...
News
Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19
Roche and Regeneron announced that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute REGN-COV2, Regeneron’s investigational antiviral antibody...
Press Releases
OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT
OSE Immunotherapeutics announced the online publication in BioRxiv of positive data from preclinical and human ex vivo studies with CoVepiT, its prophylactic vaccine program...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
